Context Therapeutics (NASDAQ:CNTX) Issues Earnings Results, Misses Estimates By $0.05 EPS

Context Therapeutics (NASDAQ:CNTX) announced its quarterly earnings data on Wednesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05), FiscalAI reports.

Context Therapeutics Stock Up 11.5%

NASDAQ:CNTX traded up $0.07 during mid-day trading on Wednesday, hitting $0.69. 2,320,160 shares of the stock traded hands, compared to its average volume of 2,293,434. The business’s 50-day moving average price is $0.95 and its 200 day moving average price is $1.93. The company has a market cap of $63.67 million, a PE ratio of -1.65 and a beta of 1.74. Context Therapeutics has a 12-month low of $0.55 and a 12-month high of $3.62.

Institutional Investors Weigh In On Context Therapeutics

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in Context Therapeutics in the fourth quarter worth $43,000. Quadrature Capital Ltd purchased a new position in shares of Context Therapeutics in the fourth quarter worth $68,000. XTX Topco Ltd grew its holdings in Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after acquiring an additional 91,008 shares during the last quarter. Citadel Advisors LLC bought a new stake in Context Therapeutics in the 3rd quarter worth $100,000. Finally, State Street Corp increased its position in shares of Context Therapeutics by 8.5% in the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after acquiring an additional 13,000 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on CNTX shares. Maxim Group dropped their price target on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.17.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.